HER2 testing in gastric cancer

Advances in Anatomic Pathology

Volumn 18, Issue 1, 2011, Pages 53-59

  Albarello, Luca ^a   Pecciarini, Lorenza ^a   Doglioni, Claudio ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

FISH; Gastric carcinoma; HER2; immunohistochemistry; trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DIAGNOSTIC TEST ACCURACY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; LOWER ESOPHAGUS SPHINCTER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REPRODUCIBILITY; STOMACH CANCER; TUMOR BIOPSY;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; ESOPHAGOGASTRIC JUNCTION; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 78650783838     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3182026d72     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24:2137-2150.
3. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin 2009;59:225-249.
4. Catalano V, Labianca R, Beretta GD, et al. Gastric cancer. Crit Rev Oncol/Hematol. 2009;71:127-164.
5. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: A phase III stduy of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). In: ASCO annual meeting, 2009, Orlando. J Clin Oncol. 2009;LBA4509.
6. Bang YJ, Van Cutsem E, Feyereislova A, et al; Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
7. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
8. Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986;319:230-234. (Pubitemid 16128786)
9. Yokota J, Yamamoto T, Toyoshima K, et al. Amplification of cerbB- 2 oncogene in human adenocarcinomas in vivo. Lancet. 1986;1:765-767.
10. Fukushige S, Matsubara K, Yoshida M, et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol. 1986;6:955-958.
11. Sakai K, Mori S, Kawamoto T, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst. 1986;77:1047-1052.
12. Yonemura Y, Ninomiya I, Yamaguchi A, et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991;51: 1034-1038.
13. Kasprzyk PG, Song SU, Di Fiore PP, et al. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res. 1992;52: 2771-2776.
14. Carter P, Presta L, Gorman CM, et al. Humanization of an antip185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89:4285-4289.
15. Gong SJ, Jin CJ, Rha SY, et al. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett. 2004;214:215-224.
16. Matsui Y, Inomata M, Tojigamori M, et al. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol. 2005;27:681-685.
17. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 2007;59:795-805.
18. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol. 2010;32:57-65.
19. Okines AFC, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer. 2010;46:1949-1959.
20. Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010;78:26-33.
21. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology. 2008;52:797-805.
22. Inui T, Asakawa A, Morita Y, et al. HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer. J Intern Med. 2006;260:484-487.
23. Rebischung C, Barnoud R, Stefani L, et al. The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein. Gastric Cancer. 2005;8:249-252.
24. Phillips K, Marshall DA, Haas JS, et al. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer. 2009;115:5166-5174.
25. Allison M. The HER2 testing conundrum. Nature Biotechnol. 2010;28:117-119.
26. EMEA, European Medicines Agency (2009): Opinion www.emea.europa.eu/pdfs/ human/opinion/Herceptin-82246709en.pdf
27. Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer:guideline validation and development of standardized immunohistochemical testing. Virchows Arch. DOI 10.1007/s00428-010-0952-2.
28. Scaltriti M, Rojo F, Ocaña A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti- HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99: 628-638.
29. Kimura M, Tsuda H, Morita D, et al. A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch. 2004;445:255-262.
30. Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2006;15:65-71.
31. Barros-Silva JD, Leitão D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009;100:487-493.
32. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2009;40: 769-777.
33. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25:118-145.
34. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5:63-69.
35. Lemoine NR, Jain S, Silvestre F, et al. Amplification and overexpression of the EGF receptor and c-erbB-2 protooncogenes in human stomach cancer. Br J Cancer. 1991;64: 79-83.
36. Kameda T, Yasui W, Yoshida K, et al. Expression of ERBB2 in human gastric carcinomas: Relationship between p185ERBB2 expression and the gene amplification. Cancer Res. 1990;50:8002-8009.
37. Bang YH, Chung H, Xu J, et al. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol. 2009; 27:15s (suppl; abstr 4556).
38. Tanner M, Hollme'n M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: Association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 2005;16:273-278.
39. Reichelt U, Duesedau P, Tsourlakis MC, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Path. 2007;20: 120-129.